Astellas Receives Positive CHMP Opinion for Zolbetuximab in Combination with Chemotherapy for Treatment of Advanced Gastric and Gastroesophageal Junction Cancer
– If approved by the European Commission, zolbetuximab would become the first and only CLDN18.2-targeted therapy approved in the European Union – A decision on the EU marketing authorization is expected by October 2024 TOKYO, July 26, 2024 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that on July … Read more
